The Experts below are selected from a list of 84 Experts worldwide ranked by ideXlab platform
E. C. Coles - One of the best experts on this subject based on the ideXlab platform.
-
A long-term five-year randomized controlled trial of hydroxychloroquine, Sodium Aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.
British journal of rheumatology, 1998Co-Authors: J. D. Jessop, Margaret O’sullivan, P. A. Lewis, L A Williams, J. P. Camilleri, M. J. Plant, E. C. ColesAbstract:Objective. To compare the efficacy of hydroxychloroquine, penicillamine, Sodium Aurothiomalate and auranofin in the treatment of active rheumatoid arthritis over a period of 5 yr. Method. Five hundred and forty-one patients with definite or classical rheumatoid arthritis were entered into an open randomized controlled trial with a flexible dose regimen designed to reflect clinical practice. Decisions to stop treatment with any one of the disease-modifying anti-rheumatic drugs (DMARDs) were based on an agreed trial protocol which defined criteria for adverse reactions and therapeutic failure. The managing physicians' decisions were confirmed in a separate monitor clinic. Results. The proportion of patients who remained on their first DMARD or who were in remission at 5 yr was 53% for penicillamine, 34% for Sodium Aurothiomalate, 31% for auranofin and 30% for hydroxychloroquine (P < 0.001). In patients who stayed on their first DMARD, all groups showed a 30-50% improvement in C-reactive protein, erythrocyte sedimentation rate, Ritchie Index and joint stiffness, and a deterioration in their Larsen score. There was no evidence of physician bias to explain the larger proportion of patients remaining on penicillamine for 5 yr. Conclusion. Despite the increased popularity of sulphasalazine and inmmunosuppressives, the drugs in this study continue to be used worldwide. The natural history of rheumatoid arthritis requires long-term follow up to establish drug efficacy. Evidence is needed as to whether the newer regimens will prove to be more effective and safer in the longer term than the commonly prescribed DMARDs. The data from this trial will provide a reference for comparison with future studies.
J. D. Jessop - One of the best experts on this subject based on the ideXlab platform.
-
A long-term five-year randomized controlled trial of hydroxychloroquine, Sodium Aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.
British journal of rheumatology, 1998Co-Authors: J. D. Jessop, Margaret O’sullivan, P. A. Lewis, L A Williams, J. P. Camilleri, M. J. Plant, E. C. ColesAbstract:Objective. To compare the efficacy of hydroxychloroquine, penicillamine, Sodium Aurothiomalate and auranofin in the treatment of active rheumatoid arthritis over a period of 5 yr. Method. Five hundred and forty-one patients with definite or classical rheumatoid arthritis were entered into an open randomized controlled trial with a flexible dose regimen designed to reflect clinical practice. Decisions to stop treatment with any one of the disease-modifying anti-rheumatic drugs (DMARDs) were based on an agreed trial protocol which defined criteria for adverse reactions and therapeutic failure. The managing physicians' decisions were confirmed in a separate monitor clinic. Results. The proportion of patients who remained on their first DMARD or who were in remission at 5 yr was 53% for penicillamine, 34% for Sodium Aurothiomalate, 31% for auranofin and 30% for hydroxychloroquine (P < 0.001). In patients who stayed on their first DMARD, all groups showed a 30-50% improvement in C-reactive protein, erythrocyte sedimentation rate, Ritchie Index and joint stiffness, and a deterioration in their Larsen score. There was no evidence of physician bias to explain the larger proportion of patients remaining on penicillamine for 5 yr. Conclusion. Despite the increased popularity of sulphasalazine and inmmunosuppressives, the drugs in this study continue to be used worldwide. The natural history of rheumatoid arthritis requires long-term follow up to establish drug efficacy. Evidence is needed as to whether the newer regimens will prove to be more effective and safer in the longer term than the commonly prescribed DMARDs. The data from this trial will provide a reference for comparison with future studies.
J Theander - One of the best experts on this subject based on the ideXlab platform.
-
Skin rashes and stomatitis due to parenteral treatment of rheumatoid arthritis with Sodium Aurothiomalate.
Annals of the rheumatic diseases, 1992Co-Authors: A Svensson, J TheanderAbstract:In a prospective study of 45 patients with rheumatoid arthritis mucocutaneous symptoms and signs were evaluated before and during treatment with intramuscular Sodium Aurothiomalate (Myocrisin). The work, performed in close collaboration between dermatology and rheumatology departments, showed that there was no significant increase in mucocutaneous side effects in patients with pre-existing mucocutaneous disease. It is concluded that pre-existing dermatitis is not a contraindication for treatment with gold salts and that a previous mucocutaneous reaction to gold salts is not an absolute contraindication for a new trial of chrysotherapy.
Shiguo Sun - One of the best experts on this subject based on the ideXlab platform.
-
In-vitro and in-vivo monitoring of gold(III) ions from intermediate metabolite of Sodium Aurothiomalate through water-soluble ruthenium (II) complex-based luminescent probe
Bioorganic chemistry, 2021Co-Authors: Zhenzhen Xie, Jia Wen, Shaowei Sun, Jing Zhang, Xiling Deng, Shichao Han, Lixia Wang, Bo Zhang, Chenglin Hong, Shiguo SunAbstract:Real-time monitoring of drug metabolism in vivo is of great significance to drug development and toxicology research. The purpose of this study is to establish a rapid and visual in vivo detection method for the detection of an intermediate metabolite of the gold (I) drug. Gold (I) drugs such as Sodium Aurothiomalate (AuTM) have anti-inflammatory effects in the treatment of rheumatoid arthritis. Gold(III) ions (Au3+) are the intermediate metabolite of gold medicine, and they are also the leading factor of side effects in the treatment of patients. However, the rapid reduction of Au3+ to Au+ by thiol proteins in organisms limits the in-depth study of metabolism of gold drugs in vivo. Here we describe a luminescence Au3+ probe (RA) based on ruthenium (II) complex for detecting Au3+ in vitro and in vivo. RA with large Stokes shift, good water solubility and biocompatibility was successfully applied to detect Au3+ in living cells and vivo by luminescence imaging, and to trap the fluctuation of Au3+ level produced by gold (I) medicine. More importantly, the luminescent probe was used to the detection of the intermediate metabolites of gold (I) drugs for the first time. Overall, this work offers a new detection tool/method for a deeper study of gold (I) drugs metabolite.
Margaret O’sullivan - One of the best experts on this subject based on the ideXlab platform.
-
A long-term five-year randomized controlled trial of hydroxychloroquine, Sodium Aurothiomalate, auranofin and penicillamine in the treatment of patients with rheumatoid arthritis.
British journal of rheumatology, 1998Co-Authors: J. D. Jessop, Margaret O’sullivan, P. A. Lewis, L A Williams, J. P. Camilleri, M. J. Plant, E. C. ColesAbstract:Objective. To compare the efficacy of hydroxychloroquine, penicillamine, Sodium Aurothiomalate and auranofin in the treatment of active rheumatoid arthritis over a period of 5 yr. Method. Five hundred and forty-one patients with definite or classical rheumatoid arthritis were entered into an open randomized controlled trial with a flexible dose regimen designed to reflect clinical practice. Decisions to stop treatment with any one of the disease-modifying anti-rheumatic drugs (DMARDs) were based on an agreed trial protocol which defined criteria for adverse reactions and therapeutic failure. The managing physicians' decisions were confirmed in a separate monitor clinic. Results. The proportion of patients who remained on their first DMARD or who were in remission at 5 yr was 53% for penicillamine, 34% for Sodium Aurothiomalate, 31% for auranofin and 30% for hydroxychloroquine (P < 0.001). In patients who stayed on their first DMARD, all groups showed a 30-50% improvement in C-reactive protein, erythrocyte sedimentation rate, Ritchie Index and joint stiffness, and a deterioration in their Larsen score. There was no evidence of physician bias to explain the larger proportion of patients remaining on penicillamine for 5 yr. Conclusion. Despite the increased popularity of sulphasalazine and inmmunosuppressives, the drugs in this study continue to be used worldwide. The natural history of rheumatoid arthritis requires long-term follow up to establish drug efficacy. Evidence is needed as to whether the newer regimens will prove to be more effective and safer in the longer term than the commonly prescribed DMARDs. The data from this trial will provide a reference for comparison with future studies.